• Glooko announced real-world study results already presented at the Diabetes Technology Society meeting evaluating EndoTool IV insulin dosing during labor and delivery.
• The retrospective analysis covered 267 pregnant individuals across 43 facilities using data from the 2025 EndoTool IV database.
• EndoTool IV supported tight blood glucose control with no recorded severe hypoglycemia, supporting its potential role in inpatient diabetes management during pregnancy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glooko Inc. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.